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Abstract: Alcoholic liver disease (ALD), a disorder caused by excessive alcohol intake represents
a global health care burden. ALD encompasses a broad spectrum of hepatic injuries including
asymptomatic steatosis, alcoholic steatohepatitis (ASH), fibrosis, cirrhosis, and hepatocellular
carcinoma (HCC). The susceptibility of alcoholic patients to develop ALD is highly variable and
its progression to more advanced stages is strongly influenced by several hits (i.e., amount and
duration of alcohol abuse). Among them, the intestinal microbiota and its metabolites have been
recently identified as paramount in ALD pathophysiology. Ethanol abuse triggers qualitative
and quantitative modifications in intestinal flora taxonomic composition, mucosal inflammation,
and intestinal barrier derangement. Intestinal hypermeability results in the translocation of viable
pathogenic bacteria, Gram-negative microbial products, and pro-inflammatory luminal metabolites
into the bloodstream, further corroborating the alcohol-induced liver damage. Thus, the premise
of this review is to discuss the beneficial effect of gut microbiota modulation as a novel therapeutic
approach in ALD management.
Keywords: alcoholic liver disease; gut microbiota; gut-liver axis; leaky gut; intestinal permeability;
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1. Introduction
Chronic alcohol consumption represents one of the most common causes of mortality worldwide [1].
According to the World Health Organization (WHO), 2.3 billion people consume alcohol in the world
and about 75 million are classified as having alcohol disorders [2]. Alcohol misuse induces damages to
multiple end organs, predominantly the liver, the gut, and the brain, thus triggering multi-systemic
injuries. In particular, the liver and to a lesser extent the gastrointestinal tract (GIT) are mainly involved
in alcohol metabolism, sustaining the greatest degree of tissue injury by heavy drinking. Alcoholic
liver disease (ALD) embraces a broad spectrum of hepatic lesions including asymptomatic steatosis,
alcoholic steatohepatitis (ASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [3].
The correlation between alcohol consumption and liver disease is now widely recognized and
the majority of individuals (90%) who regularly consume more than 40–60 g/day of alcohol develop
steatosis. If the affected individual ceases drinking, steatosis is a reversible condition. However,
in 20–40% of dependent drinkers, steatosis may be complicated by inflammation and fibrosis while
cirrhosis develops in about 10–20% [4]. HCC annually occurs in 2–3% of alcohol-related cirrhosis [5–7]
and only half of the patients are eligible for therapeutic treatments (liver transplantation, resection,
and percutaneous ablation) [7]. In patients with alcohol use disorders (AUD), ALD and cirrhosis
are the leading causes of death [8]. Therefore, there is an urgent need to develop novel therapeutic
interventions for patients affected by severe alcoholic hepatitis.
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The susceptibility of alcoholic patients to develop ALD is highly variable. The progression of
ALD to more advanced conditions is strongly influenced by several issues, i.e., amount and duration of
alcohol abuse, age, gender, ethnicity, comorbidities, nutritional status and by environmental, inherited,
and epigenetic factors that also cause differences in susceptibility to liver damage [9]. Among these
factors, recent evidence has pointed out to the role of gut microbiota and its metabolites in the
pathophysiology of ALD. Indeed, alcohol consumption is responsible for substantial modifications of
quality and quantity of intestinal flora (condition referred to as dysbiosis), to mucosal alteration and to
enhanced gut permeability, resulting in endotoxemia [10]. Specifically, the increased gut permeability
due to alcohol abuse leads to higher lipopolysaccharide (LPS) concentration into portal blood flow
which bind to Toll-like receptor 4 (TLR4) and activate nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-κB) stimulating in turn, pro-inflammatory cytokines release, reactive oxygen
species (ROS) production, and oxidative stress. All these events may induce the activation of resident
macrophages, the Kupffer cells and hepatic stellate cells (HSCs), perpetuating inflammation and
fibrosis in the liver [11,12].
For this reason, this review aimed to focus on the relevance of gut microbiota modulation in
the development and progression of ALD and its promising role as potential diagnostic strategy and
therapeutic target in the personalized ALD management.
2. Insight into the Gut Microbiota
The gut is the largest reservoir of microorganisms in the body. Indeed, the human gastrointestinal
lumen is the physiological habitat for a variety of microbes (bacteria, archaea, fungi, yeast, and viruses).
It includes tens of trillions of microbial cells belonging to several different species, which is approximately
ten-times the number of somatic cells in the human body and they carry more than three million
unique genes [13,14]. The majority of bacterial species belongs to the phyla Firmicutes (Gram positive)
and to Bacterioidetes (Gram negative), while the remnants to Actinobacteria, Fusobacteria, Proteobacteria,
and Verrucomicrobia [15–17]. The GIT and the intestinal flora are in symbiotic relationship. Indeed,
the 85% of total bacteria, such as Lactobacilli and Bifidobacteria, are commensal organisms, whereas the
others, such as Clostridium and Fusobacterium, could potentially become pathogens [18].
The exact role of microbiota remains largely unexplored. However, the presence of microbes in
the gut participates in vitamin (i.e., vitamin B) and amino acid synthesis, macromolecule catabolism,
energy providing, drug and toxin metabolism, and intestinal barrier preservation. All imbalances
or alterations in intestinal flora taxonomic composition and/or function are generally indicated as
‘dysbiosis’ [19]. In particular, alterations of microbiota homeostasis have an impact not only on
alcohol-related liver disorders, but they have been also associated with type II diabetes (T2DM) [20],
obesity [21,22], inflammatory bowel disease (IBD) [23], irritable bowel syndrome (IBS) [24], celiac
disease [25], cancer [26], and many others. Indeed, gut microbiota interacts with the host, avoiding the
pathogenic bacteria over-growth, modulating the immune system and the immunological tolerance of
mucosal cells, and stimulating the production of pathogen-specific immunoglobulin A (IgA) [27].
The concentration and the composition of bacterial species are different along the entire GIT
with inter-individual variation depending on the age, ethnicity, lifestyle, medications, and dietary
habits [18]. Alcohol consumption along with the Western diet, enriched in animal fat and sugars,
bowel movement frequency, genetics, and disruption of circadian rhythms can predispose to dysbiosis,
as demonstrated in a large number of studies in rodents [28,29] and humans [30–34].
The physiological function of the intestinal flora in the production of metabolites (i.e., endotoxins,
bile acids, and short chain fatty acids (SCFAs), products of fermentation of unabsorbed food residues,
mainly carbohydrates used as energy source for the host) can be assessed using metabolomic, proteomic,
and transcriptomic approaches. Indeed, the intestinal, systemic, uric, and fecal concentration of
bacterial products potentially reflects the microbiota composition and may be exploited as a diagnostic
noninvasive marker. In addition, sequencing of the 16S ribosomal RNA (rRNA) gene through
next-generation DNA sequencing is widely used to determine the bacterial community diversity
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and their relative abundance in mucosa-associated colonic tissue biopsies and in fecal samples.
This technique is now also flanked by the more expensive metagenomics shotgun approaches [34].
2.1. Preclinical Models of Alcohol-Induced Microbiota Alterations
Alcohol misuse facilitates intestinal bacterial over-growth predominantly in the upper small
bowel, both in preclinical and human models [29,30]. Preclinical models are particularly helpful in the
understanding of the implications of the ethanol administration on dysbiosis and bacterial over-growth.
Alcohol-fed mice for three weeks developed ALD, related to qualitative changes in the intestinal
microflora due to small intestinal bacterial over-growth, dysbiosis in the cecum and suppression of gene
and protein expression of bactericidal c-type leptins Regenerating islet-derived protein 3 b (Reg3b) and
Reg3g in the small intestine. Moreover, even anti-microbial molecules against Gram-positive bacteria
contribute to enteric dysbiosis, observed after ethanol consumption [29]. These mice demonstrated
an unbalance of bacterial families, displaying a reduction of bacteria from the phylum Firmicutes and
conversely an enhanced abundance of Bacterioidetes and Verrucomicrobia. However, after the treatment
of ethanol-fed mice with probiotics, Reg3g protein levels were partially restored, rescuing alcoholic
steatohepatitis. In another study, Mutlu and colleagues evidenced that rats intragastrically fed alcohol
daily for ten weeks displayed an altered colonic mucosa-associated bacterial composition leading
to ileal and colonic dysbiosis [28]. These changes support the role of gut microbiota composition in
alcohol-induced injuries both in intestine and in the liver, contributing also to alteration of intestinal
barrier integrity and release of pro-inflammatory mediators into the portal circulation. Moreover,
both Lactobacillus GG (LGG) or oats prevented the alcohol-induced colonic dysbiosis in this model.
The severity of alcohol-induced liver injury is associated with a specific microbiota signature
in ALD patients and the degree of susceptibility to alcohol-induced liver injury is transmissible
from patients to mice through fecal microbiota transplantation (FMT). Germ-free mice fed ethanol
develop severe liver inflammation, necrosis, and greater intestinal permeability, when transplanted
with the gut microbiota isolated from patients with severe alcoholic hepatitis compared to those that
received intestinal microbiota from alcoholic subjects without alcoholic hepatitis [35]. According
to this notion, the transfer of intestinal flora from alcoholic patients without alcoholic hepatitis
ameliorates alcohol-induced liver lesions, demonstrating that intestinal bacteria play a causative
role in the disease development. The bacterial species mainly involved in the deleterious effect of
severe ALD transmission included altered Bacteroides phylum as well as Bilophila wadsworthia, Alistipes,
Butyricimonas, Clostridium, Proteus, and Escherichia Coli. Conversely, intestinal microbiota isolated
from patients with advanced alcoholic hepatitis displays hampered concentration of Faecalibacterium
prausnitzii, a microbial species with anti-inflammatory and mucosal protective properties producing
butyric acid [36] and of Akkermansia muciniphila, that resides in mucin barrier [35]. Importantly, butyric
acid is known as a regulator of gluconeogenesis and energy homeostasis [37]. Llopis and coworkers
demonstrated, for the first time, that the susceptibility to ALD is reversible through restoring eubiosis,
thus paving the way for a personalized medicine [35]. Analyzing the differences in fecal metabolome,
the most striking discriminant metabolites were the bile acids (i.e., the antioxidant ursodeoxycholic acid
(UDCA) was reduced in alcohol-fed mice). The presence of ALD-associated microbiota was related also
to a marked reduction of mucins (predominantly Muc2), Reg3b and Reg3g expressions, contributing to
dysbiosis and to increase the amount of the adherent bacteria and to bacterial translocations [29].
Nonetheless, changes in the mycobiome composition, i.e., Candida spp. overgrowth, induces
also the translocation of β-glucans into systemic circulation and antifungal treatment results in
the improvement of alcohol-induced liver injuries [38]. All these events may influence the host
susceptibility to ALD.
2.2. Impact of Alcohol Consumption on Human Gut Microbiota
Changes in gut microbiota due to the alcohol misuse have been suggested as a key factor in
the development of ALD and alcohol-related morbidity and they have been largely explored in
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several studies [30–32,39–45]. In particular, chronic alcohol overconsumption favors small intestinal
malabsorption and modification of colonic bacteria balance, altering also gut microbiota metabolism,
as it has been previously demonstrated by Steinar Traae Bjørkhaug and colleagues by using the d-xylose
breath test [46]. This approach was extensively used in the past years as a tool to diagnose small
intestinal bacterial overgrowth, taking advantage of the microbial ability to metabolize d-xylose and to
assess the effective absorption area of the small intestine [46]. In this study, the authors determined that
chronic alcohol overconsumption causes malabsorption comparable to what was observed in patients
with untreated celiac disease, and that it may alter gut microbial metabolism [46]. This phenomenon is
usually described with the term ‘leaky gut’.
More recently, Traae Bjorkhaug and colleagues analyzed the variability in the intestinal bacterial
composition in patients with chronic alcohol overconsumption compared to those with no or very low
history of alcohol intake [45]. These patients had a potentially more inflammatory active microbiota
along with an over-representation of Proteobacteria (Gram-negative, increasing endotoxins in the
blood) in the gut, at the phylum level, and a particular increase in the genera Clostridium, Holdemania
(Firmicutes), and Sutterella (Proteobacteria). On the contrary, they showed a lower amount of the genus
Faecalibacterium, as previously demonstrated in preclinical studies, that is generally considered to be
protective against gastrointestinal conditions. Moreover, among the assessed SCFA, the authors found
a lower concentration of butyric acid, beneficial for the maintenance of the intestinal barrier integrity,
in the feces of alcohol over-consumers. Indeed, the composition of intestinal bacteria influences the
amount and the type of metabolites produced.
All these results are in line with the previous studies in which lower amounts of Bacteroidetes
and Lactobacillus species and a higher abundance of Proteobacteria and Fusobacteria in alcoholics have
been found [31,32]. To date, the reason for the bacterial overgrowth remain unexplained. However,
since alcohol can reduce the gastrointestinal motility, this has been proposed as a pivotal mechanism
for fecal stasis and lumen bacterial proliferation. Nonetheless, even the suppression of innate and
adaptive immune response could exert a direct effect on intestinal microbiota alterations.
Overall, alcoholics and cirrhotic patients demonstrate a microbial community enriched in
Proteobacteria of the class Gammaproteobacteria and Firmicute of the class of Bacilli, and the degree of the
over-growth correlates with the severity of the liver damage [41]. Furthermore, even the enhanced
presence of the pathogenic families of Enterobacteriaceae and Streptococcaceae and the decreased of
Akkermansia muciniphila are strictly correlated with the severity of alcoholic hepatitis [35,47]. All these
alterations are also accompanied by increasing concentrations of secondary bile acids, paralleling
the liver damage worsening [35]. The restoration of the balance of these microorganisms improved
alcohol-associated hepatic injury and gut barrier function in a mouse model of ALD [47]. However,
specific changes in the class of Clostridia may differ between ALD and alcohol-related cirrhosis, possibly
identifying the stage of the liver disease.
Finally, a decrease in fungal diversity and an over-representation of Candida species in patients
with AUD, independently of liver disease stage, has been observed [38].
3. Physiological Functions of Gut Barrier
The bidirectional flux between the gut and the liver through the biliary tract, portal vein,
and systemic circulation represents a crucial player on liver pathology. In particular, the liver modulates
gut microbiota composition, exerting multiple functions (i.e., bile acid production) and participating
with the enterohepatic circulation which is accountable for the responsiveness to gut bacterial
end-products and nutrients received via the portal vein. The gut-liver also axis has implications for the
intestinal immune response, intestinal barrier function, and hepatic and systemic inflammation [36].
The intermediate frontier that separates the gut-liver axis is represented by the intestinal barrier,
comprising multiple layers that line the intestine and protect the hosts from microorganism invasion.
This barrier is not only a selectively permeable physical barrier constituted by juxtaposed epithelial
intestinal cells held together by tight junctions (occludins, claudins, and zonula occludens 1 (ZO-1)),
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adherent junctions and desmosomes, but also has immunological properties, due to the presence of
the mucus edge. The intestinal mucus layer is composed by mucin (predominantly Muc2 in small
and large intestine) secreted by goblet cells and acts as a physical, chemical, and immunological
barrier, protecting also mucosal cells against exogenous agents. Indeed, it may serve as binding sites
for commensal microorganisms on the surface, that are considered a barrier for the colonization of
pathogens. Moreover, selected commensal species from different phyla, as the Akkermansia muciniphila,
exploit the mucin oligosaccharide chains as a carbon source. In germ-free rats, the depletion of
microbiota induces an imbalance between mucus production and degradation, leading to a doubling in
the thickness of the mucus layer and swelling of the cecum due to the accumulation of mucus, and the
resulting retention of water [48]. The excessive erosion of the protective mucus layer, conversely,
has been associated with pathogens over-growth.
The inner portion of the mucus, instead, is sterile. In this region, the intestinal epithelial cells
and the immune cells (Paneth cells) secrete antimicrobial peptides (for example defensins, lysozyme,
and c-lectin Reg3g) and IgA produced by plasma cells, in order to largely devoid the migration of
bacteria into the inner mucus layer. Interesting, the majority of IgA produced in the gut are not reactive
to the commensal microbiota. The reduction of these mediators is associated with bacterial over-growth
in both preclinical and human studies [49]. Intestinal over-expression of Reg3g may prevent the effect
of chronic alcohol consumption on liver damage in mice, even in presence of increased intestinal
permeability [49].
An additional defense against microorganism invasion is constituted by a lamina propria,
which connects the surface of the mucosal epithelium to the basement muscolaris mucosae, localized
in the sub-epithelial space along with its resident population of innate and adaptative immune cells.
It regulates the translocation of antigens and prevents microbial displacement. However, in case of
microorganism translocation through the intestinal epithelium to the bloodstream, they are eliminated
by lamina propria-resident macrophages or engulfed by dendritic cells and carried to mesenteric
lymph nodes [50].
The gut-associated lymphoid tissue (GALT), consisting in isolated or aggregated lymphoid follicles
forming Peyer’s patches in small intestine, is also an extremely important component of the intestinal
barrier. It contains the majority of the immunoglobulin-secreting cells of the entire body, by hosting
naïve immune cells differentiation into a variety of mature immune cell subsets [50].
Finally, even blood vessels, smooth muscle cell layers and components of the enteric nervous
system (ENS), guarantee the intestinal barrier function by regulating the mucosa and by initiating
specific defense programs in case of microorganism invasions [51].
4. Hallmarks of Alcohol Misuse in Intestinal Barrier Integrity
The disruption of the intestinal barrier function is relevant for alcohol-induced liver pathology
and its etiology is multifactorial. After two weeks of alcohol administration in rodents, the leakiness of
the intestinal barrier is evident, and then, after another two weeks, endotoxemia and hepatic injuries
occur [52]. Ethanol and its metabolites may alter gut permeability exerting a direct deleterious effect
on the adherence junctions and on tight junction integrity such as ZO-1, as a consequence of increase
oxidative stress burden in the intestine [53,54]. It also induces mucus erosions and ulcerations modifying
the glycosylation of the protective mucus layer and potentially the abundance and composition of the
adherent bacterial species [55].
Furthermore, the alteration in microflora taxonomic composition and dysregulation of bile acid
metabolism, that usually occurs in ALD patients, may trigger the dysfunction of barrier properties and
enhance intestinal permeability. Therefore, dysbiosis may contribute to intestinal hypermeability, and in
particular, the exaggerated presence of Proteobacteria may favor an intestinal mucosa inflammation [56].
In addition, microbial metabolites, such as SCFAs (butyrate, acetate, and propionate), that have been
reported to be altered after alcohol consumption, may affect the intestinal barrier integrity and mucosal
immune tolerance [57]. For example, Faecalibacterium prausnitzii, a member of Firmicutes phylum
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that is down-modulated in ALD patients, is an example of microbial species producing butyric acid.
The reduction of this microbial product weakens the firm connection between the intestinal epithelial
cells, by decreasing the expression of the tight junction proteins and of mucins [58,59]. The restoration
of the physiological abundance of microorganisms producing butyrate, in turn, may ameliorate the
gut high permeability and systemic inflammation [60]. Finally, the increasing intestinal expression of
several microRNAs (miRNAs; i.e., miR-122 and miR-212), short non-protein coding single-strands
RNAs involved in the regulation of cell–cell cross-talk, may also affect gut barrier integrity by targeting
ZO-1, claudins, and occludins, as shown in both Caco-2 cells and mice enterocytes [9].
The enhanced intestinal permeability facilitates the translocation, from the intestinal lumen
to extraintestinal space, of viable pathogenic bacteria, Gram-negative microbial products, and pro-
inflammatory luminal metabolites into the blood circulation, contributing to liver damage [28,61].
Lipoteichoic acid, flagellin, bacterial hypomethylated (CpG) DNA, and other gut- derived toxins are
released in the blood flow and are implicated in the development of ALD. Among them, endotoxins (LPS)
and peptidoglycans are the most representative. When these pathogenic antigens reach the liver via
the portal vein, they are enabled to induce the activation of the inflammatory processes [62], becoming
responsible not only for the worsening of hepatic injury, but also for mortal infections in cirrhotic
patients [62]. The massive exposure of the liver parenchyma to LPS may be relevant for inflammatory
and fibrogenic processes perpetuation. Indeed, LPS stimulates the innate immunity response, through
the binding to TLR4 and its co-receptor CD14, activating in turn NF-κB and interleukin-6/signal
transducer and activator of transcription 3 (IL6/STAT3) signaling in Kupffer cells, macrophages,
and HSCs. Moreover, peptidoglycans, components of Gram-positive bacteria, interact with TLR2 on
circulating peripheral blood mononuclear cells (PBMCs) thus eliciting inflammatory responses [63].
Similarly, chronic alcohol consumption favors intestinal fungal translocation into systemic circulation,
contributing to liver inflammation via C-type lectin-like receptor (CLEC7A) on Kupffer cells and
bone marrow derived cells [38]. As a consequence of these interactions, pro-inflammatory mediators
are secreted, such as chemokines and cytokines (TNFα and IL1β), free radicals, and leukotrienes,
exacerbating the inflammation on the substrate of already damaged hepatocytes by the alcohol
consumption. TLR4 deficient mice exhibit less severe liver injury after alcohol administration,
supporting the role of endotoxins in liver injury onset [12]. The impairment of intestinal barrier may
lead also to bacterial displacement to mesenteric lymph nodes, further corroborating the systemic
inflammation [64].
The diagnostic approaches to study the modifications of the intestinal barrier functionality are
essential for staging ALD progression. Therefore, several strategies for the assessment of structural
impairment of this barrier have been developed [65]. These strategies mainly exploit the analyses of
flux rates across the intestinal wall of defined inert molecules, that can be adequately measured in
blood and in urine. For instance, the oral administration of the indigestible and radioactive probe
51Cr-EDTA and its dosage in urine is widely used to investigate the permeability of the whole intestine.
Conversely, to specifically address the analyses of the small intestine permeability, the ingestion of
non-metabolizable oligosaccharides of large size, e.g., lactulose or sugars of small size, e.g., mannitol
or l-rhamnose, are generally used [51]. These techniques may be also flanked by the assessment of
serum/plasma and fecal biomarkers and bacterial metabolites dosage, and by breath tests, assessing
the bacterial compounds exhaled.
The impact of alcohol overconsumption on intestinal barrier integrity disruption is schematically
represented in Figure 1.
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Figure 1. Role of ‘leaky gut’ in progressive ALD. In this figure, we reported a schematic illustration of the
main alterations that contribute to alcohol-induced liver injury. Excessive alcohol abuse (Et-OH) exerts
a direct detrimental effect on the intestinal barrier integrity by affecting the tight junction protein (i.e.,
zonula occludens 1 (ZO-1)) expression and mucus layer. Physiologically, mucus (Muc2) is produced by
the goblet cells, instead, the Paneth cells (immune cells) secrete antimicrobial peptides (i.e., c-lectin
Reg3b/g), that contribute to maintain the inter-species bacterial balance. Alteration in quality/quantity
of microflora taxonomic composition (referred to as ‘dysbiosis’) may trigger the dysfunction of barrier
properties and enhance intestinal permeability. The hyperpermeability facilitates the translocation into
the enterohepatic circulation of viable pathogenic bacteria, Gram-negative microbial products, mainly
lipopolysaccharides (LPS). LPS, peptidoglycans, and β-glucans bind Toll-like receptor 4 (TLR4)/CD14
complex, TRL2, and C-type lectin-like receptor (CLEC7A), respectively, and mediate the activation
of hepatic Kupffer cells and peripheral blood mononuclear cells (PBMCs), via NF-κB and IL6/STAT3
signaling. Activated Kupffer cells and PBMCs, in turn, release a large amount of pro-inflammatory
cytokines and chemokines (such as TNFα and IL1β), further perpetuating the hepatic inflammation
and oxidative stress in the context of already damaged hepatocytes. These events can even contribute
to the worsening of hepatic injury to advance stages, favoring also the activation of hepatic stellate cells
(HSCs), involved in fibrogenic processes.
Impact of Bile Acids on Intestinal Barrier Integrity
Emerging evidence has suggested that alterations in bile acids metabolism are associated
with alcohol-related disorders and hepatic comorbidities, i.e., development of cholestasis. In the
physiological status, the liver synthetizes bile acids and releases them into the duodenum lumen as
conjugated metabolites which participate in enterohepatic cycling upon gut microbial modifications.
In particular, bile acid activation of intestinal farnesoid X receptor (FXR) leads to the transcription of
fibroblast growth factor 19 (FGF19), which in turn modulates gut barrier integrity and downregulates
bile acids synthesis in the liver [66]. Alcohol consumption reduces FXR expression as well as stimulates
cholesterol 7-α hydroxylase 1 (Cyp7A1) hepatic activity, resulting in higher bile acid pool in the liver.
Indeed, actively drinking patients with cirrhosis increased fecal secondary bile acids (deoxycholic
acid (DCA) and lithocholic acids) compared to healthy control or abstinent cirrhotic individuals [67].
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Furthermore, higher levels of DCA may prevent the growth of beneficial members of Bacteroidetes and
Firmicutes phyla, leading to HSCs activation and increased risk of HCC development [68].
5. Gut Microbiota: The Mirror of your Addiction
Recent evidence suggests that modifications in the composition of gut microbiota and its
metabolites may influence the brain functions and behavioral aspects [69]. In particular, alcohol-induced
enhanced intestinal permeability and endotoxemia may affect phycological status and cognitive
ability, reinforcing the drinking tendency. The proof of this concept has been provided by Leclercq
and colleagues who showed that in noncirrhotic patients hospitalized for alcohol detoxification,
the increasing intestinal permeability and LPS serum dosage were significantly correlated with higher
scores of depression, anxiety, decreased social interactions, and ethanol cravings, even after alcohol
withdrawal [70]. The ‘leaky gut’, indeed, may alter central nervous system (CNS) functionality.
Nevertheless, in ALD-cirrhotic patients, systemic inflammation, endotoxemia, and hyperammonemia
are strictly connected with the manifestation of hepatic encephalopathy [71]. The systemic inflammation
induces a detrimental direct effect on neurons and favors the disruption of the blood-brain barrier
(BBB) and the passage of activated peripheral immune cells, thus enhancing the ethanol-induced
neuroinflammation mainly in microglia and astrocytes [72]. Microbial metabolic products may also
have a strong impact on peripheral inflammation and brain barrier integrity. Gut bacteria produce
neurotransmitters (such as serotonin, gamma-aminobutyric acid (GABA), dopamine, acetylcholine),
and bacterial fermentation of dietary fiber induces the release of SCFAs with potential neuroactive
properties [64]. For instance, butyric acid mainly derived from Firmicutes, may influence the
immune milieu of brain through changing peripheral immune system function and attenuating
neuroinflammation. In addition, it regulates serotonin and gut hormone levels in the enteric nervous
system [73]. Serotonin is a neurotransmitter that can modulate intestinal motility through its 5-HT
receptors on different cell types of the GIT, mainly enterocytes, enteric neurons, and immune cells
and, given its role in humor regulation, the effect of microbiota composition on social behavior could
be explained.
Several studies support the notion that antimicrobials, probiotics, and high fiber butyrate-
producing diets may positively influence the health of the brain, ameliorating memory and
cognition [74].
6. Promising Therapeutics to Modulate Gut Microbiota in ALD
Current standards of care for the management of ALD patients aim to prevent either liver
damage onset or progression by encouraging alcohol abstinence. However, the efficacy of treatments
is highly dependent from disease severity and the ability to overcome alcohol withdrawal with
appropriate psychological and pharmacological approaches, which has success rates between 20–40%
of remission [75,76]. The global burden of alcohol-related deaths and disabilities is estimated to be
3.8% and 4.6%, respectively, and most of these are due to alcoholic cirrhosis and liver failure [77,78].
To date, liver transplantation represents a potential lifesaving indication for the end-stage of liver
disease in ALD candidates. However, this topic is much-debated from both medical and ethical
grounds as it is regarded as a “self-inflicted disease” and also due to the ever-increasing demand
of donor organs combined with alcohol relapse and cravings [78]. Regardless the stage of disease,
alcohol abstinence is considered the cornerstone of therapy as it improves hepatic histology and
survival of ALD patients [79]. Nevertheless, around 5–10% of ALD patients are at risk to develop
fibrosis and cirrhosis even if they cease drinking [80]. Thus, there is an urgent need to develop novel
therapeutic interventions.
Several pre-clinical and human studies strive to explore how alcohol-induced gut microbiota
alterations may contribute to liver disease progression whose mechanism remains still unclear.
Otherwise, most of them showed an association between ethanol-induced microbiota unbalancing
in the GIT, bacterial overgrowth and development of liver pathology. Therefore, intensive efforts
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have been directed to investigate potential therapeutic strategies aimed to modulate intestinal bacteria
composition through 1) untargeted approaches, including diet, probiotics, prebiotics, antibiotics,
fecal microbiota transplant (FMT) or 2) precision medicine by selectively targeting microbial and host
metabolites [81].
6.1. Effects of Diet on Gut Microbiota Communities
Research in animal models and clinical studies have widely demonstrated that the composition
of gut microflora may be influenced by genetic, lifestyle, and environmental factors, including
dietary intake, which further account for the inter-individual variability of the intestinal bacterial
strains. Specific diets, such as high-fat diet (HFD) and Western diet, have been associated with
the overgrowth of pro-inflammatory bacterial species, affecting intestinal pH, gut barrier integrity,
and favoring LPS transition into the blood flow [82]. These alterations may promote the predisposition
to gut microbiota-related disorders, thus paving the way to the study of the effects of diet to reverse
alcohol-associated dysbiosis [83–86].
Both long and short-term dietary changes can rapidly normalize intestinal microflora,
thus representing a simple and effective approach to restore eubiosis. The major differences in
microflora composition have been observed between people consuming Western diet and subjects
with high-fiber dietary habits. An interesting finding has been carried out on American volunteers,
who were randomized to receive an animal-based diet (meats, eggs, and cheese) or a plant-based diet
(cereals, legumes, fruits, and vegetables). It showed an increment of bile-tolerant species (Alistipes,
Bilophila, and Bacteroides) and reduced levels of Roseburia, Eubacterium rectale, and Ruminococcus bromii
which metabolized dietary plant polysaccharides in individuals under an animal-based regimen [68,87].
Dietary fibers, encompassing complex carbohydrates and oligosaccharides, exert great health
benefits as a result of intestinal fermentative metabolism mediated by colonic bacteria that produce
SCFAs. Zymmer et al. analyzed the fecal samples of vegan and vegetarian individuals and
found a significant reduction of Bidifobacterium and Bacteroides species similarly to what previously
observed by Aries et al. who compared English subjects consuming a mixed Western diet to Africans
feeding high-carbohydrate vegetarian diet [88,89]. Also, diet-enriched in carbohydrates and fibers
was responsible for lower stool pH (between 5.5 and 6.5) probably due to the end-products of
gut fermentative metabolism thereby inhibiting pathogenic bacteria overgrowth like Escherichia
coli and Enterobacteriacee [82,88,90,91]. Long-term fibers consumption is further associated with a
prevalence of Prevotella, whose levels are generally diminished with animal-based diet. However,
certain species belonging to the phyla of Bacteroidetes, such as Prevotella copri and Bacteroides
vulgatus have been associated with insulin resistance. Conversely, members of Verrucomicrobiaceae
and Ruminococcaceae, like Akkermansia muciniphila and Faecalibacterium prausnitzii, respectively,
which improve insulin sensitivity, decreased in different animal models fed with HFD [92–96]
and alcohol administration [36,97].
Finally, many natural extracts have been found to have hepatoprotective impact on ALD.
Dietary polyphenols provided by coffee, green tea, and chocolate have shown beneficial effects by
directly interacting with gut microbial communities. Grape polyphenols attenuated the effects of
HFD–induced metabolic syndrome (MetS) in C57Bl/6 mice, improving glucose intolerance, levels of
serum inflammatory markers, and intestinal barrier integrity. Furthermore, Akkermansia muciniphila
was dramatically increased while a lower Firmicutes to Bacteroidetes ratio was observed [96]. Flaxseed
oil improves inflammatory responses and stimulates Firmicutes and Parabacteriodes overgrowth in ALD
mice [98]. Rhubarb and Litchi chinensis Sonn. phenol extracts promote eubiosis, restore intestinal
barrier dysfunction and protect from liver inflammation in animal models of binge drinking [97,99].
The benefits of diet-enriched in phenols have been related to the amelioration of alcohol-induced
hepatic damage [97] and even more to lower risk of hospitalization in cirrhotic patients [100].
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6.2. Nutritional Strategies Affecting Intestinal Bacterial Species: Probiotics, Prebiotics, and Synbiotics
Nowadays, the value of the caloric intake overcomes its basic role to provide the necessary
nutrients for daily energy demand, but it is acquiring particular attention to prevent a wide spectrum
of diseases, i.e., cardiovascular diseases, obesity, allergies, and cancer. Extensive research has been
focused on the beneficial effects of probiotics, prebiotics, or synbiotics consumption.
The WHO defines probiotics as “life microorganisms which—when administered in adequate
amounts—confer a health benefit on the host” [101]. The most representatives are Lactobacillus and
Bifidobacterium that promote anti-inflammatory environment by enhancing intestinal epithelium growth
and survival as well as they may counteract the pathogenic bacteria by producing anti-microbial
agents and modulating immune system and host defense [102–104]. For instance, Lactobacillus reuteri
strains formed biofilms which dampen TNFα production by LPS-activated monocytic cells [103],
whilst Lactobacillus salivarius and Bifidobacterium infantis attenuate intestinal inflammation reducing
the pro-inflammatory production of Th1-type cytokines [105]. Lactobacillus rhamnosusGG (LGG)
was the first probiotic tested in a rodent model of ALD and it was effective to improve ‘leaky gut’
and hepatic inflammation either alone or enriched with oat fibers [106]. Administration of LGG
showed protective effects on ethanol-induced liver injury, circulating liver enzymes, such as alanine
aminostransferase (ALT) and aspartate aminostransferase (AST), and endotoxemia in Wistar rats [107].
Likewise, the short-term oral treatment with Bifidobacterium bifidum and Lactobacillus plantarum 8PA3 in
a randomized study encompassing 66 alcoholic patients was associated with microflora renewal and
significantly lowered AST and ALT levels compared to the standard therapy [108]. An open-label study
carried out on 12 alcoholic cirrhotic subjects receiving Lactobacillus casei Shirota 3 times daily for 4 weeks
showed that probiotic consumption restored neutrophil phagocytosis possibly by down-regulating
interleukin (IL) 10 secretion and TLR4 expression [109]. Recently, it has been demonstrated that mice
feeding Lieber-DeCarli diet supplemented with Akkermansia muciniphila were protected against acute
and chronic ALD as proven by reduced expression of pro-inflammatory cytokines, systemic endotoxins,
and restoration of ethanol-induced intestinal barrier dysfunction [110]. Probiotic VSL#3, a mixture of
8 probiotic strains (mainly Lactobacillus and Bifidobacterium), prevented changes in tight junction protein
expression thus protecting the intestinal barrier function and limited endotoxins transition from the
gut lumen to the portal circulation in a rat model of acute ALD [111]. Interestingly, Loguercio and
co-workers evaluated the effects of a fixed therapy with probiotic VSL#3 in patients affected by different
chronic liver diseases, including 20 ALD patients. Similarly, to pre-clinical studies, they observed
improvement in circulating cytokines and oxidative/nitrosative stress parameters and even more in
liver pathology [112].
Among nutraceutical strategies used to modify gut microbiota composition, even prebiotics
revealed appealing molecules which can attenuate hepatic lesions in both animal models and
humans. Prebiotics are non-digestible fibers helpful as substrates for Lactobacillus and Bifidobacteria
proliferation [113] and also they should present several features, including: 1) resistance to acids,
bile salts, and hydrolyzing enzymes in the stomach; 2) reaching the large intestine without
being absorbed in the upper GIT; and, finally 3) being easily metabolized by nonpathogenic
flora [113,114]. The group of prebiotics predominantly tested includes fructo-o-oligosaccharides
(FOS), galacto-oligosaccharides (GOS), arabinoxylan-oligosaccharides, inulin, and prebiotics from
natural sources (chicory and yacon roots, etc). Over the past years, few studies investigated the
prebiotic efficacy in alcoholic models, while no clinical trials have been reported in ALD patients. Inulin,
FOS, and GOS consumption increase the abundance of Bifidobacterium adolescentis, Bifidobacterium
catenulanum, Lactobacillus spp, and Faecalibacterium prausnitzii while they lower levels of Bacteroides spp
and Clostridium spp with supplement-containing fructans [82,115–117]. Ethanol diet-enriched in inulin
provided beneficial effects on gut bacteria composition and hepatic injury through raising the amount
of Allobaculum, Lactobacillus, and Lactococcus species and suppressing the LPS-activated TLR4 signaling
on the hepatic macrophages (Mψ) in C57BL/6J mice [118]. Additionally, Yan and collaborators analyzed
the transcriptome in a mouse model of continuous intragastric ethanol infusion, revealing that chronic
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alcohol assumption down-regulated the expression of Reg3b and Reg3g, whose levels were retrieved
upon FOS administration [29].
Finally, synbiotics are evolving as new therapeutics to manage gastrointestinal, metabolic and liver
diseases. The term “synbiotic” refers to as synergistic mechanism as combines probiotics with prebiotic
compounds, which selectively stimulate probiotic bacteria survival enhancing their beneficial effects.
FloraGuard®, a synbiotic powder enriched in prebiotics and Lactobacillus acidophilus, Lactobacillus
bulgaricus, Bifidobacterium bifidum, Bifidobacterium longum, and Streptococcus thermophilus, added to an
ethanol diet ameliorated hepatic steatosis and inflammation but also improved gut permeability in
Wistar rats [119]. In a very recent pre-clinical study, C57BL/6 mice chronically exposed to binge ethanol
feeding were protected against hepatic steatosis and liver injury whether they were supplemented
with Faecalibacterium prausnitzii and potato starch, probably due to increased levels of butyrate and
propionate transport into the hepatocytes [120]. Unfortunately, further clinical investigations are
required to look into their efficacy for ALD prevention and treatment.
6.3. Antibiotics
The long-term administration of antibiotics in therapy is controversial due to side-effects which
may occur in patients (i.e., antibiotic resistance, hepatotoxicity, disruption of the gut ecosystem,
etc.) [121,122]. However, several experimental models revealed that endotoxemia and alcoholic
hepatitis were prevented with antibiotics prophylaxis [123–125]. Several classes appear eligible
to counteract Gram-negative microbial overgrowth in humans. In particular, rifaximin has been
approved for alcohol-related cirrhosis as a preventive strategy of hepatic encephalopathy. It is a
nonabsorbable derivative of rifampicin, with broad-spectrum of anti-microbial activities by binding to
the β-subunit of bacterial DNA-dependent RNA polymerase [126]. In 2012, the phase 2 interventional
non-randomized clinical trial (NCT01069133) on rifaximin administration was completed. It has
tested the ability of rifaximin therapy to ameliorate the brain functionality in 20 cirrhotic patients
with subclinical form of hepatic encephalopathy. Rifaximin usage was significantly associated with
the improvement in cognitive performance and in endotoxemia, showing a shift from pathogenic to
beneficial metabolites [127].
6.4. Fecal Microbiota Transplantation (FMT): An Uncharted Territory
Fecal microbiota transplantation (FMT), defined as the transfer of stool matter from a healthy
donor into the intestinal tract of a recipient, is currently representing an ongoing attractive avenue
for gut microbiota editing, although it requires further investigation due to several concerns about
safety and potential infectivity. However, encouraging results have been observed in patients with IBD
or chronic hepatopathies. In 1958, Eiseman et al. published the first successful FMT in patients with
severe pseudomembranous colitis (PMC), even though it was not known that Clostridium difficile was
the leading cause of developing PMC. Currently, FMT has become a lifesaving procedure for recurrent
Clostridium difficile infection [128].
Regardless the routes of FMT administration (i.e., capsules, nasogastric /nasojejunal/ endoscopic
tubing, etc.), the mechanism by which it may confer health benefits include changes in bacterial
species, favoring nonpathogenic microbes’ overgrowth which, in turn, produce antimicrobial agents
(bacteriocins) [129]. Interestingly, FMT from healthy donors to a mouse model of chronic ethanol
exposure significantly decreased alcohol-related anxiety and depression thus suggesting gut microbiota
as a potential target to treat alcohol addiction [130]. Other pre-clinical artwork underlined the
promising role of FMT to modulate gut microbiota in models of ulcerative colitis (UC) as well
as in both gastrointestinal and non-gastrointestinal diseases [131–134]. In a recent pilot study,
Philips et al. showed that FMT improved gut dysbiosis and clinical outcomes of steroid-ineligible
patients with severe alcoholic hepatitis. Moreover, they observed changes in relative abundance of
pathogenic (Klebsiella pneumonia) and nonpathogenic species (Enterococcus villorum, Bifidobacterium
longum, and Megasphaera elsdenii), suggesting that donor microbiota do not replace but rather modify
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the recipient flora as a proof-of-concept [135]. Nonetheless, the potential therapeutic of FMT in ALD
need to be better elucidated.
6.5. Microbiota-Targeted Therapy: The New Frontier of Medicine
Nutritional strategies, antibiotics, and FMT have been shown to provide advantages to human
health despite exerting broad-spectrum, non-specific effects in modulating intestinal microbiota
and byproducts. Thus, new challenges in medicine are gambling on microbiota-targeted therapies
(i.e., restoring microbial metabolites, bio-engineered bacteria, and modulation of microbiota pathways)
for the clinical diagnosis and prevention of several diseases [36]. These approaches require an in-depth
knowledge of metagenomics, host-microbiota interactions, and properties of microbial communities.
Excessive alcohol consumption leads to reduced intestinal butyrate, whose levels along with
gut injury and inflammatory markers of liver disease were recovered with prophylactic tributyrin
supplementation in a mouse model of ethanol exposure [58–60]. Metagenomic and targeted metabolome
analysis underlined saturated long-chain fatty acids (LCFAs), which are metabolized by Lactobacilli to
promote their growth, and bile acid intermediates as potential therapeutics in chronic-binge alcohol
models. As expected, the abundance of Lactobacilli correlated to LCFAs levels in fecal samples of
alcoholic patients and mice feeding an ethanol diet showed a down-regulation in LCFAs synthesis.
Furthermore, LCFAs added to alcohol administration foster Lactobacillus proliferation and improved
hepatic damage in these mice [136]. Additionally, treatment with fexaramine, a FXR agonist, or
overexpression of FGF19 normalized intestinal barrier and ethanol-induced liver disease in mice [137].
Finally, bio-engineered bacteria have been designed to precisely counteract pathogen-induced
dysbiosis by secreting beneficial molecules in the GIT. Escherichia coli Nissle 1917 (EcN) modified to
produce pyrroloquinoline quinone (PQQ) ameliorated liver injury in a rat model of acute alcohol
consumption [138]. Hendrikx et al. have recently transformed Lactobacillus reuteri to produce IL22
which stimulates the intestinal expression of Reg3g. In both binge drinking mice and humans,
ethanol reduced several tryptophan metabolites that, normally, induce the expression of IL22 in innate
lymphoid cells type 3 (ILC3). Therefore, mice receiving bio-engineered Lactobacillus reuteri restored
levels of both IL22 and Reg3g and further improved alcoholic steatohepatitis [139].
7. Focus on Ongoing Clinical Trials
The restoration of microbial composition, the modulation of bacterial metabolites and FMT from
healthy individuals may represent the subjects of larger and long-term clinical trials. Antibiotics are
currently used in clinical care to protect cirrhotic patients against complications, such as spontaneous
bacterial peritonitis and hepatic encephalopathy. To date, the use of rifaximin as a possible antifibrotic
drug which modulates human gut microbiota is under exploration in a biopsy-controlled, double-blind
study (EudraCT, 2014-001856-51) [140]. The dietary fiber usage (inulin supplementation) in ALD
patients is under definition even in the interventional study NCT03803709. The normalization of
alcohol-related dysbiotic signatures with anti-fibrotic purpose is also the topic of a randomized
study, which is based on the administration of Profermin Plus®, composed by fermented oats,
Lactobacillus Plantarum 299v, barley malt, and lecithin, to ALD patients (NCT03863730). Phase I of
a randomized, single-blind study is currently recruiting patients with alcohol-induced advanced
fibrosis with the aim to ameliorate the inflammation and to improve the prognosis of these patients,
after dysbiosis resetting by exploiting FMT (NCT03416751). Furthermore, several randomized
control clinical trials point out FMT as a beneficial and safe therapeutic approach in severe ALD,
fibrosis, and hepatic encephalopathy (NCT04014413, NCT02862249, NCT02424175, NCT02400216,
NCT02496390, NCT01968382, NCT03091010, NCT03827772) [36]. Finally, even the exploration of
gut–brain axis in alcohol cue-induced craving is under examination in the observational clinical trial
NCT03152760. A schematic description of the main ongoing clinical trials is represented in Table 1.
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Table 1. Clinical trials currently underway addressing the therapeutic modulation of gut microbiota in ALD patients.
Clinical Trial
Start-End Date Status Study Type Interventions Conditions Objectives Locations
EudraCT,
2014–001856-51
08/14-ongoing
Recruiting
(n = 136) *
Interventional
Randomized
550 mg of rifaximin
twice daily for 18
months vs placebo
Biopsy-verified
alcoholic fibrosis
Anti-fibrotic and molecular aspects of
rifaximin in ALD
Odense University Hospital (Odense,
Denmark)
NCT03803709
07/17–07/22
Recruiting
(n = 40) *
Interventional
Randomized
Dietary Supplement:
inulin
vs. placebo
Alcoholism
Restore a nutritional balance via a dietary
fiber intake
And study the intestinal and psychological
well-being related to a fiber intake
Université catholique de Louvain
Brussels, Belgium
NCT03863730
04/19–02/31
Recruiting
(n = 40) *
Interventional
Randomized
Dietary Supplement:
Profermin Plus,
vs. Fresubin, dietary
supplement
Advanced ALD
Demonstrate that the alcohol-related
dysbiosis can be reversed improving the
disease progression by modulating
microbiota with probiotics for 24 weeks.
FLASH—Centre of Liver Research
Odense, Fyn, Denmark
Odense University Hospital
Odense, Denmark
NCT04014413
07/19–10/24
Not yet recruiting
(n = 450) *
Interventional
Non-Randomized FMT ASH, IBS, T2DM, MetS
Investigate the efficacy and safety of FMT in
a variety of dysbiosis-associated disorder
The Chinese University of Hong Kong
Hong Kong, Shatin, Hong Kong
NCT02862249
03/18–08/20
Recruiting
(n = 32) *
Interventional
Randomized
(Phase 3)
FMT vs. placebo
ALD abstinent from
alcohol for a minimum
of 6 weeks
Assess whether restoring gut microbiota
with FMT in patients with advanced
cirrhosis is both feasible and safe
King’s College Hospital NHS Foundation
Trust Recruiting
London, United Kingdom
NCT03091010
04/17–04/19
Recruiting
(n = 130) *
Interventional
Randomized FMT vs. steroids
Severe Alcoholic
Hepatitis
Compare FMT and steroid therapy in
patients with Severe Alcoholic Hepatitis
Institute of Liver and Biliary Sciences
New Delhi, Delhi, India
NCT03827772
01/19–12/19
Recruiting
(n = 40) *
Interventional
Non-Randomized
FMT vs. standard of
care treatment
Severe Alcoholic
Hepatitis
Evaluate the role of FMT on short term
survival and improvement in scores of
prognostic significances (CTP, MELD,
MELDNa, mDF) in patients with Severe
Alcoholic Hepatitis
Postgraduate Institute of Medical Education
and Research
Chandigarh, India
NCT03416751
01/18–12/19
Recruiting
(n = 20) *
Interventional
Randomized
(Phase 1)
FMT vs. placebo CirrhosisAlcohol Abuse
Demonstrate that FMT ameliorates
inflammation and prognosis of ALD
cirrhotic patients
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, United States
NCT03152760
08/17–12/20
Recruiting
(n = 69) *
Observational
Case-control NA Alcoholism
Observe the changes in gut bacteria that
may occur in people with AUD
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
* Estimated number of participants; NA, not applicable.
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8. Concluding Remarks
Through different routes, gut microbiota composition and function are strongly entangled in
the pathogenesis and the progression of liver injury in patients who misuse alcohol. In particular,
alcohol-induced dysbiosis along with several other issues concur to increase individual susceptibility
to ALD. To date, clinical guidelines indicate alcohol abstinence, corticosteroids, or pentoxifylline,
or surgical interventions as a gold standard in the treatment of ALD. Therefore, there is an urgent need
to identify novel therapeutic strategies to tailor ALD management. Several studies and clinical trials
have suggested that intestinal microflora modulation by exploiting probiotics, prebiotics, synbiotics,
or FMT will represent a turning point in the care of ALD patients. Trustworthily, addressing gut
microbiota as a new frontier of future medicine will brighten the avenue of personalized interventions,
as well, act as a lighthouse in the stormy sea.
Nevertheless, microbiota composition investigation could become an appealing candidate even for
diagnosis, attempting to stage liver disease. However, further studies are essential to completely draft
the true causality between changes observed in the context of alcohol misuse and hepatic morbidities
as well as to pinpoint the mechanisms through which microbiota alterations affect liver pathology in
ALD patients. Up to now, the enigma remains to be unraveled: Who is the guilty?
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Abbreviations
ALD Alcoholic Liver Disease
ALT Alanine Aminostransferase
ASH Alcoholic Steatohepatitis
AST Aspartate Aminostransferase
AUD Alcohol Use Disorder
BBB Blood-Brain Barrier
CNS Central Nervous System
CLEC7A C-type lectin-like receptor
Cyp7A1 Cholesterol 7-α hydroxylase 1
DCA Deoxycholic Acid
EcN Escherichia coli Nissle 1917
ENS Enteric Nervous System
Et-OH Ethanol
FGF19 Fibroblast Growth Factor 19
FMT Fecal Microbiota Transplantation
FOS Fructo-o-oligosaccharides
FXR Farnesoid X Receptor
GABA Gamma-aminobutyric acid GABA
GALT Gut-associated lymphoid tissue
GIT Gastrointestinal Tract
GOS Galacto-oligosaccharides
HCC Hepatocellular Carcinoma
HFD High Fat Diet
HSCs Hepatic Stellate Cells
IBD Inflammatory Bowel Disease
IBS Irritable Bowel Syndrome
IgA Immunoglobulin A
IL1β Interleukin-1 Beta
IL10 Interleukin 10
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IL22 Interleukin 22
IL6/STAT3 Interleukin-6/ Signal Transducer and Activator of Transcription 3
ILC3 Innate Lymphoid Cells Type 3
LCFA Long-Chain Fatty Acids
LGG Lactobacillus rhamnosus GG
LPS Lipopolysaccharides
MetS Metabolic Syndrome
miRNAs microRNAs
Mψ Hepatic Macrophages
NF-κB Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells
PMBCs Peripheral blood mononuclear cells
PMC Pseudomembranous Colitis
PQQ Pyrroloquinoline Quinone
Reg3b Regenerating islet-derived protein 3 b
Reg3g Regenerating islet-derived protein 3 g
ROS Reactive Oxygen Species
SCFA Short Chain Fatty Acid
T2DM Type 2 Diabetes Mellitus
TLR4 Toll-like receptor 4
TNFα Tumor Necrosis Factor alpha
UC Ulcerative colitis
UDCA Ursodexycholic acid
WHO World Health Organization
ZO-1 Zonula Occludens-1
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